PT1443938E - Unidade de dosagem compreendendo um análogo de prostaglandina para o tratamento de obstipação - Google Patents

Unidade de dosagem compreendendo um análogo de prostaglandina para o tratamento de obstipação Download PDF

Info

Publication number
PT1443938E
PT1443938E PT02780083T PT02780083T PT1443938E PT 1443938 E PT1443938 E PT 1443938E PT 02780083 T PT02780083 T PT 02780083T PT 02780083 T PT02780083 T PT 02780083T PT 1443938 E PT1443938 E PT 1443938E
Authority
PT
Portugal
Prior art keywords
dosage unit
prostaglandin analog
treating constipation
constipation
treating
Prior art date
Application number
PT02780083T
Other languages
English (en)
Inventor
Ryuji Ueno
Myra L Patchen
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1443938(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of PT1443938E publication Critical patent/PT1443938E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings
PT02780083T 2001-11-14 2002-11-14 Unidade de dosagem compreendendo um análogo de prostaglandina para o tratamento de obstipação PT1443938E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14

Publications (1)

Publication Number Publication Date
PT1443938E true PT1443938E (pt) 2011-09-27

Family

ID=23293447

Family Applications (2)

Application Number Title Priority Date Filing Date
PT100102110T PT2298314E (pt) 2001-11-14 2002-11-14 Unidade de dosagem compreendendo um análogo de prostaglandina para o tratamento de obstipação
PT02780083T PT1443938E (pt) 2001-11-14 2002-11-14 Unidade de dosagem compreendendo um análogo de prostaglandina para o tratamento de obstipação

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT100102110T PT2298314E (pt) 2001-11-14 2002-11-14 Unidade de dosagem compreendendo um análogo de prostaglandina para o tratamento de obstipação

Country Status (15)

Country Link
US (3) US8097653B2 (pt)
EP (2) EP2298314B1 (pt)
JP (2) JP4852229B2 (pt)
AR (3) AR037524A1 (pt)
AT (1) ATE522218T1 (pt)
BR (1) BR0214075A (pt)
CA (1) CA2464420C (pt)
CY (1) CY1115856T1 (pt)
DK (2) DK2298314T3 (pt)
ES (2) ES2368729T3 (pt)
HK (1) HK1155649A1 (pt)
LU (1) LU92826I2 (pt)
PT (2) PT2298314E (pt)
TW (1) TWI331920B (pt)
WO (1) WO2003041716A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
CA2510051C (en) 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
PL1871380T3 (pl) * 2005-04-12 2012-03-30 Sucampo Ag Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych
EP1978944B1 (en) * 2006-01-24 2012-08-15 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
EP1984027B1 (en) 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) * 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
DE69213057T2 (de) * 1991-03-14 1997-01-09 R Tech Ueno Ltd Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
PH31171A (en) * 1992-02-04 1998-03-20 Esai Co Ltd Aminobenzonic acid derivatives useful for treatinggastrointestinal conditions.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
DE69714698T2 (de) * 1996-06-10 2002-12-05 Sucampo Ag Endothelin-antagonisten
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
AU739343B2 (en) 1997-11-28 2001-10-11 Sucampo Ag Endothelin antagonist
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
JP4332316B2 (ja) * 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
AU4472701A (en) 2000-04-06 2001-10-23 Sucampo Ag Bile secretion promoting composition
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
BR0209863A (pt) 2001-05-18 2004-06-08 Sucampo Ag Composição catártica
BR0212233A (pt) 2001-08-31 2004-10-05 Sucampo Ag Abridor de canal de cloreto
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
CA2510051C (en) 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Also Published As

Publication number Publication date
DK2298314T3 (en) 2014-12-01
ES2524369T3 (es) 2014-12-05
HK1155649A1 (en) 2012-05-25
JP2011201905A (ja) 2011-10-13
LU92826I2 (fr) 2015-11-24
JP2005513014A (ja) 2005-05-12
CA2464420A1 (en) 2003-05-22
AR098997A2 (es) 2016-06-22
PT2298314E (pt) 2014-12-03
US20030119898A1 (en) 2003-06-26
US8389542B2 (en) 2013-03-05
AR037524A1 (es) 2004-11-17
EP2298314A1 (en) 2011-03-23
TWI331920B (en) 2010-10-21
EP1443938A1 (en) 2004-08-11
BR0214075A (pt) 2004-09-28
US20120088824A1 (en) 2012-04-12
DK1443938T3 (da) 2011-09-26
ES2368729T3 (es) 2011-11-21
AR117404A2 (es) 2021-08-04
ATE522218T1 (de) 2011-09-15
JP4852229B2 (ja) 2012-01-11
CA2464420C (en) 2011-12-13
CY1115856T1 (el) 2017-01-25
TW200300091A (en) 2003-05-16
EP2298314B1 (en) 2014-09-03
US8097653B2 (en) 2012-01-17
WO2003041716A1 (en) 2003-05-22
EP1443938B1 (en) 2011-08-31
US20130143958A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
HK1155649A1 (en) Dosage unit comprising a prostaglandin analog for treating constipation
GB0023983D0 (en) Therapeutic compounds
GB0008710D0 (en) Therapeutic compounds
GB0016681D0 (en) Therapeutic compounds
AU1233002A (en) Medicament dispenser
GB0031084D0 (en) Pharmaceutical compounds
GB0028583D0 (en) Therapeutic compounds
GB9900222D0 (en) Therapeutic compounds
GB0019272D0 (en) Pharmaceutical compounds
GB0024318D0 (en) Pharmaceutical compounds
AU2002343222A1 (en) Dosage unit comprising a prostaglandin analog for treating constipation
GB0005366D0 (en) Pharmaceutical compounds
GB0013105D0 (en) Therapeutic compounds
IL151017A0 (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
GB0013650D0 (en) Therapeutic compounds
GB0023984D0 (en) Therapeutic compounds
GB0023986D0 (en) Therapeutic compounds
GB0029383D0 (en) Therapeutic compounds
GB0023982D0 (en) Therapeutic Compounds
GB0022347D0 (en) Therapeutic compounds
GB0014561D0 (en) Therapeutic compounds
GB0013652D0 (en) Therapeutic compounds
GB0013649D0 (en) Therapeutic compounds
GB0013648D0 (en) Therapeutic compounds
GB0003767D0 (en) Therapeutic compounds